These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 20640541)

  • 41. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results.
    Medeot M; Zaja F; Vianelli N; Battista M; Baccarani M; Patriarca F; Soldano F; Isola M; De Luca S; Fanin R
    Eur J Haematol; 2008 Sep; 81(3):165-9. PubMed ID: 18510702
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia.
    Chapin J; Lee CS; Zhang H; Zehnder JL; Bussel JB
    Am J Hematol; 2016 Sep; 91(9):907-11. PubMed ID: 27220625
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mycophenolate mophetil therapy for chronic immune thrombocytopenic purpura resistant to steroids, immunosuppressants, and/or splenectomy in adults.
    Colović M; Suvajdzic N; Colović N; Tomin D; Vidović A; Palibrk V
    Platelets; 2011; 22(2):153-6. PubMed ID: 21142405
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of Children with Persistent and Chronic Idiopathic Thrombocytopenic Purpura: 4 Infusions of Rituximab and Three 4-Day Cycles of Dexamethasone.
    Oved JH; Lee CSY; Bussel JB
    J Pediatr; 2017 Dec; 191():225-231. PubMed ID: 29173312
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies.
    Blase JR; Frame D; Michniacki TF; Walkovich K
    Front Immunol; 2022; 13():863177. PubMed ID: 35514985
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration.
    Bussel JB; Lee CS; Seery C; Imahiyerobo AA; Thompson MV; Catellier D; Turenne IG; Patel VL; Basciano PA; Elstrom RL; Ghanima W
    Haematologica; 2014 Jul; 99(7):1264-71. PubMed ID: 24747949
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia.
    Arnold DM; Heddle NM; Carruthers J; Cook DJ; Crowther MA; Meyer RM; Liu Y; Cook RJ; McLeod A; MacEachern JA; Mangel J; Anderson D; Vickars L; Tinmouth A; Schuh AC; Kelton JG
    Blood; 2012 Feb; 119(6):1356-62. PubMed ID: 22223819
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Childhood immune thrombocytopenia: role of rituximab, recombinant thrombopoietin, and other new therapeutics.
    Journeycake JM
    Hematology Am Soc Hematol Educ Program; 2012; 2012():444-9. PubMed ID: 23233617
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience.
    Al Askar AS; Shaheen NA; Al Zahrani M; Al Otaibi MG; Al Qahtani BS; Ahmed F; Al Zughaibi M; Kamran I; Mendoza MA; Khan A
    Int J Hematol; 2018 Jan; 107(1):69-74. PubMed ID: 28895035
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura.
    Stasi R; Stipa E; Masi M; Cecconi M; Scimò MT; Oliva F; Sciarra A; Perrotti AP; Adomo G; Amadori S
    Am J Med; 1995 May; 98(5):436-42. PubMed ID: 7733121
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia.
    Mahévas M; Gerfaud-Valentin M; Moulis G; Terriou L; Audia S; Guenin S; Le Guenno G; Salles G; Lambotte O; Limal N; Viallard JF; Cheze S; Tomowiak C; Royer B; Neel A; Debouverie O; Hot A; Durieu I; Perlat A; Cliquennois M; Deteix C; Michel M; Godeau B
    Blood; 2016 Sep; 128(12):1625-30. PubMed ID: 27354722
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Maintenence rituximab following induction in autoimmune cytopenias.
    Rai MP; Lee EJ; Bussel JB
    Br J Haematol; 2023 Jul; 202(1):153-158. PubMed ID: 37086173
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.
    Jovancevic B; Lindholm C; Pullerits R
    Lupus; 2013 Jun; 22(7):664-74. PubMed ID: 23612795
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sustained complete remission of chronic refractory immune thrombocytopenic purpura (ITP) of 10 years duration after only two infusions of rituximab.
    Cohen Y; Polliack A
    Hematol J; 2002; 3(1):61-2. PubMed ID: 11960398
    [No Abstract]   [Full Text] [Related]  

  • 55. Refractory autoimmune thrombocytopenic purpura: responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab).
    Narang M; Penner JA; Williams D
    Am J Hematol; 2003 Dec; 74(4):263-7. PubMed ID: 14635207
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rituximab Therapy in Adults with Refractory Symptomatic Immune Thrombocytopenia: Long-Term Follow-Up of 15 Cases.
    Hindilerden F; Yönal-Hindilerden İ; Yenerel MN; Nalçacı M; Diz-Küçükkaya R
    Turk J Haematol; 2017 Mar; 34(1):72-80. PubMed ID: 27102929
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Rituximab treatment for adults with steroid-resistant idiopathic thrombocytopenic purpura].
    Wang W; Yu QH; Zhang HY; Chu XX; Chen F; Zhang CQ; Zhou YH; Hou M
    Zhonghua Nei Ke Za Zhi; 2008 Mar; 47(3):225-7. PubMed ID: 18785508
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia.
    Hegde UP; Wilson WH; White T; Cheson BD
    Blood; 2002 Sep; 100(6):2260-2. PubMed ID: 12200396
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term outcomes of patients treated with rituximab as second-line treatment for adult immune thrombocytopenia - Follow-up of the RITP study.
    Tjønnfjord E; Holme PA; Darne B; Khelif A; Waage A; Michel M; Ben Romdhan N; Ghanima W
    Br J Haematol; 2020 Nov; 191(3):460-465. PubMed ID: 32342497
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical efficacy and tolerability of vincristine in splenectomized patients with refractory or relapsed immune thrombocytopenia: a retrospective single-center study.
    Park YH; Yi HG; Lee MH; Kim CS; Lim JH
    Int J Hematol; 2016 Feb; 103(2):180-8. PubMed ID: 26588926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.